Therefore, early prediction of whether pCR will be achieved after NACT treatment is of great clinical significance for HER2-positive breast cancer patients and can assist clinicians to adjust treatment regimens as early as possible It can assist clinicians in making early adjustments to treatment regimens, reduce unnecessary toxic effects of chemotherapy, increase pCR rates, and improve patient prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.